Patients 0 8 0 8 O
who 9 12 9 12 O
have 13 17 13 17 O
an 18 20 18 20 O
ongoing 21 28 21 28 O
SAE 29 32 29 32 O
from 33 37 33 37 O
a 38 39 38 39 O
clinical 40 48 40 48 O
study 49 54 49 54 O
that 55 59 55 59 O
is 60 62 60 62 O
assessed 63 71 63 71 O
by 72 74 72 74 O
the 75 78 75 78 O
investigator 79 91 79 91 O
as 92 94 92 94 O
related 95 102 95 102 O
to 103 105 103 105 O
bardoxolone 106 117 106 117 B-treatment
methyl 118 124 118 124 I-treatment

Unwilling 0 9 125 134 O
to 10 12 135 137 O
practice 13 21 138 146 O
acceptable 22 32 147 157 O
methods 33 40 158 165 O
of 41 43 166 168 O
birth 44 49 169 174 O
control 50 57 175 182 O
( 58 59 183 184 O
both 59 63 184 188 O
males 64 69 189 194 B-gender
who 70 73 195 198 O
have 74 78 199 203 O
partners 79 87 204 212 O
of 88 90 213 215 O
childbearing 91 103 216 228 O
potential 104 113 229 238 O
and 114 117 239 242 O
females 118 125 243 250 B-gender
of 126 128 251 253 O
childbearing 129 141 254 266 O
potential 142 151 267 276 O
) 151 152 276 277 O
while 153 158 278 283 O
taking 159 165 284 290 O
study 166 171 291 296 O
drug 172 176 297 301 O

Women 0 5 302 307 B-gender
who 6 9 308 311 O
are 10 13 312 315 B-pregnancy
pregnant 14 22 316 324 I-pregnancy

have 0 4 325 329 O
completed 5 14 330 339 O
required 15 23 340 348 O
End 24 27 349 352 O
- 27 28 352 353 O
of 28 30 353 355 O
- 30 31 355 356 O
Treatment 31 40 356 365 O
and/or 41 47 366 372 O
Follow 48 54 373 379 O
- 54 55 379 380 O
up 55 57 380 382 O
visits 58 64 383 389 O
in 65 67 390 392 O
a 68 69 393 394 O
prior 70 75 395 400 O
clinical 76 84 401 409 O
study 85 90 410 415 O
with 91 95 416 420 O
bardoxolone 96 107 421 432 B-treatment
methyl 108 114 433 439 I-treatment

